Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Isosorbide Mononitrate

Isosorbide Mononitrate: A Comprehensive Guide

Introduction

Isosorbide mononitrate is a widely used medication that belongs to the nitrate class of drugs, primarily indicated for the prevention and long-term treatment of angina pectoris. Derived from isosorbide dinitrate, it is a more stable and predictable metabolite with improved bioavailability, making it an essential tool in managing chronic coronary artery disease.

Isosorbide Mononitrate

Isosorbide mononitrate is an organic nitrate that functions by dilating blood vessels, which reduces the workload on the heart and improves the oxygen supply to the heart muscle. It is often prescribed in an extended-release form for once-daily use, making it convenient for long-term management.

Mechanism of Action

Isosorbide mononitrate works by releasing nitric oxide (NO) in the smooth muscle of blood vessels. Nitric oxide activates guanylate cyclase, which increases the levels of cyclic guanosine monophosphate (cGMP). Elevated cGMP levels cause dephosphorylation of myosin light chains, leading to relaxation of smooth muscle cells and vasodilation. The primary action is venodilation, which decreases preload (the volume of blood returning to the heart), and to a lesser extent, arterial dilation, which reduces afterload. These effects collectively reduce myocardial oxygen demand.

Clinical Uses

1. Chronic Stable Angina

The main indication for isosorbide mononitrate is the prophylactic treatment of angina pectoris. It helps reduce the frequency and severity of anginal attacks by minimizing the oxygen demand of the heart.

2. Heart Failure (Off-label)

In certain cases, particularly in patients intolerant to ACE inhibitors or beta-blockers, isosorbide mononitrate may be used in combination with hydralazine to manage heart failure with reduced ejection fraction (HFrEF).

3. Pulmonary Hypertension (Off-label)

Though not first-line, it may be considered as adjunct therapy to reduce pulmonary pressures and improve symptoms.

Pharmacokinetics

  • Absorption: Rapid and nearly complete after oral administration.

  • Bioavailability: High due to lack of first-pass metabolism (unlike isosorbide dinitrate).

  • Time to Peak Concentration: 30-60 minutes for immediate-release, 5-6 hours for extended-release.

  • Half-life: 5–6 hours.

  • Metabolism: Primarily hepatic.

  • Excretion: Mainly via the kidneys as inactive metabolites.

Dosage and Administration

Immediate-Release Tablets:

  • Typically initiated at 10-20 mg twice daily.

  • The second dose is usually taken 7 hours after the first to allow for a nitrate-free interval and prevent tolerance.

Extended-Release Tablets:

  • A common starting dose is 30-60 mg once daily in the morning.

  • May be increased to a maximum of 120 mg once daily depending on patient response.

Titration:

Dose adjustment is based on clinical response, with attention to avoiding tolerance.

Side Effects

Common Side Effects:

  • Headache (most frequent due to vasodilation)

  • Dizziness or lightheadedness

  • Nausea

  • Flushing

  • Hypotension

Serious Side Effects:

  • Severe hypotension

  • Syncope

  • Reflex tachycardia

  • Paradoxical angina (rare)

Most side effects are dose-related and improve with continued use or proper titration.

Tolerance and Nitrate-Free Interval

One of the biggest challenges with long-term nitrate therapy is tolerance. Continuous exposure can lead to decreased effectiveness. To prevent this, it is crucial to schedule a nitrate-free interval of at least 8-12 hours each day, which is why extended-release formulations are designed with this interval in mind.

Drug Interactions

Contraindicated with:

  • Phosphodiesterase inhibitors (e.g., sildenafil, tadalafil): Can cause life-threatening hypotension.

  • Riociguat: Also contraindicated due to risk of hypotension.

Caution with:

  • Antihypertensive agents (e.g., beta-blockers, calcium channel blockers): Additive hypotensive effects.

  • Alcohol: Enhances vasodilation and orthostatic hypotension.

Contraindications

  • Severe hypotension

  • Shock or circulatory failure

  • Hypersensitivity to nitrates

  • Concurrent use with PDE-5 inhibitors

Special Populations

Elderly:

Greater sensitivity to hypotensive effects; start at lower doses.

Pregnancy and Lactation:

Category C drug; use only if clearly needed. Effects during breastfeeding are not well established.

Renal and Hepatic Impairment:

May require dose adjustment; monitor closely.

Monitoring Parameters

  • Blood pressure and heart rate

  • Frequency and severity of angina

  • Signs of orthostatic hypotension

  • Tolerance development over time

Patient Counseling Tips

  • Do not crush or chew extended-release tablets.

  • Avoid alcohol while on this medication.

  • Stand up slowly from sitting or lying positions to avoid dizziness.

  • Do not stop suddenly; tapering may be needed.

  • Inform your doctor if chest pain increases or if headaches persist.

  • Avoid using erectile dysfunction medications while on isosorbide mononitrate.

Comparison with Isosorbide Dinitrate

Feature Isosorbide Mononitrate Isosorbide Dinitrate
Bioavailability Higher Lower (first-pass effect)
Half-life Longer Shorter
Dosing Frequency Once daily (ER) Multiple times daily
Tolerance Risk Lower Higher
Metabolites Active Inactive

Isosorbide mononitrate is preferred for its once-daily dosing, improved patient compliance, and better pharmacokinetic profile.

Recent Research and Developments

Recent studies are exploring the role of isosorbide mononitrate in combination with other drugs for heart failure management. There's also ongoing research on modified-release formulations to better mimic the body's circadian rhythm and reduce tolerance. One study published in the Journal of the American College of Cardiology suggested that intermittent nitrate therapy may be more effective than continuous use, particularly in elderly populations prone to hypotension and nitrate tolerance.

Conclusion

Isosorbide mononitrate continues to be a cornerstone in the prophylactic treatment of angina and has proven benefits in reducing the frequency of anginal attacks and improving quality of life in patients with ischemic heart disease. Its favorable pharmacokinetic profile, once-daily dosing, and well-established efficacy make it a reliable choice in long-term cardiovascular care. However, as with any medication, individual considerations, potential side effects, and drug interactions must be carefully managed. Health professionals must ensure that patients are educated on its proper use, including the importance of nitrate-free intervals to prevent tolerance.